The latest estimates on the antiviral molnupiravir were released Nov. 26 and come from a trial with 1,433 participants. The drug cut the risk of hospitalization or death from 9.7 percent in the placebo group to 6.8 percent among those who received molnupiravir, for a relative risk reduction of 30 percent.
Merck’s earlier estimates from Oct. 1, which found the antiviral cut the risk of hospitalization or death by 48 percent, were based on an analysis of 775 participants.
The antiviral is intended to treat mild to moderate COVID-19 in adults at high risk for severe disease progression, according to the drugmaker.
The FDA is set to meet Nov. 30 to decide whether to approve molnupiravir under an emergency use authorization.
Meanwhile, the FDA is also reviewing Pfizer’s COVID-19 antiviral drug, Paxlovid, which reduced the risk of hospitalization or death by 89 percent in a phase 3 clinical trial.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.